At a glance
- What the study gets you
- Access to the study treatment being tested
- Type of study
- Interventional (receives a drug or procedure)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- Pirtobrutinib (drug), Idelalisib (drug)
- How long the study runs
- Study runs about 81 months (dates as stated)
- About the drug or intervention
- Pirtobrutinib — drug: Administered orally · Idelalisib — drug: Administered orally
- Patient visit burden
- Not specified by the sponsor
- Type of study
- Testing a treatment
- Ages
- 18 Years and over
- Who
- All
- Number of participants
- 150
- Started
- 2026-03-09
- Last checked
- 2026-09
Plain English Summary
What is this study?
- • Testing a new treatment for chronic lymphocytic leukemia
- • Phase4 - 150 participants
- • This study will evaluate the long-term safety of pirtobrutinib in participants with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
Who can take part?
- • Ages 18 Years and over
- • Diagnosed with chronic lymphocytic leukemia
Where?
- • Hull - Castle Hill Hospital
- • Leeds - St James's University Hospital
- • Newmarket - GenesisCare
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
This study will evaluate the long-term safety of pirtobrutinib in participants with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study is open to those who completed J2N-MC-JZNN/LOXO-BTK-20020 (NCT 04666038) for continued access to the study intervention or continued follow-up visits. Treatment will be given every 4 weeks and this study is expected to last about 5 years.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 18 Years and over
- Who can join: All genders
What the study is looking for
- ✓Are actively participating in study J2N-MC-JZNN/LOXO-BTK-20020
Who cannot take part
- ✗This is not applicable to this study
See the full criteria
Where Is This Study? (3 UK sites)
Castle Hill Hospital
Hull HU16 5JQ, United Kingdom
St James's University Hospital
Leeds LS9 7TF, United Kingdom
GenesisCare
Newmarket CB8 7XN, United Kingdom
How to Get in Touch
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Sponsor contactCONTACT
Physicians interested in becoming principal investigators please contact
Sponsor contactCONTACT